DZL scientists discover novel, attractive therapeutic strategy to treat PH with an active ingredient from the walnut.
Pulmonary hypertension is a common co-morbidity of COPD. Previous studies have already established that (in the experimental model) pulmonary vascular changes precede the development of emphysema.
In a webinar for the non-profit self-help association pulmonale hypertonie (ph) e. V., Prof. Werner Seeger vividly describes how the treatment of pulmonary hypertension has evolved to date.
Patients with severe idiopathic pulmonary fibrosis (IPF) often develop additional pulmonary hypertension. A clinical trial investigated whether treatment with Sildenafil (approved for PH) when administered in addition to the pulmonary fibrosis medication pirfenidone is effective.
A research team from Hannover with participation of the DZL have published a study on molecular markers for various forms of pulmonary hypertension in the American Journal of Pathology.
The collaborative research center 1213 for cardiopulmonary research in Giessen, spear-headed by DZL scientist Prof. Dr. Norbert Weissmann, will be funded by the German Re-search Foundation (DFG) for another four years. The first funding period...
Pulmonary Arterial Hypertension (PAH) is a progressive, fatal disease of the pulmonary vasculature. Affected patients have a poor prognosis, and treatment options are limited.
The DZL was represented with an information desk at the 60th Congress of the German Respiratory Society (DGP), which took place in Munich from March 13–16, 2019.